GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd EBIT Margin for the year ending December 31, 2023: 20.28%

GuiZhou SanLi Pharmaceutical Co.,Ltd EBIT Margin is 20.28% for the year ending December 31, 2023, a 7.74% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

GuiZhou SanLi Pharmaceutical Co.,Ltd EBIT Margin for the year ending December 31, 2022 was 18.82%, a -2.00% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd EBIT Margin for the year ending December 31, 2021 was 19.21%, a 15.44% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd EBIT Margin for the year ending December 31, 2020 was 16.64%, a -3.37% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd EBIT Margin for the year ending December 31, 2019 was 17.22%, a -4.62% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years